EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy

Ahmad Masri iD, Francesco Cappelli iD, Margot K Davis, Marianna Fontana iD, Pablo Garcia-Pavia iD, Julian D Gillmore iD, Mazen Hanna, Laura Obici iD, Scott D Solomon iD, Brett W Sperry iD, Nobuhiro Tahara iD, Márcia Waddington-Cruz iD und 9 weitere

Circulation: Heart Failure · 2026-06 · 19 (6)

DOI: 10.1161/circheartfailure.126.014205 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation: Heart Failure, 2026-06. Verfasst von Ahmad Masri und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Oregon Health and Sciences University, Portland (A.M.). Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies, Oligonucleotides, Antisense, Prealbumin. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Transthyretin amyloidosis with cardiomyopathy is a progressive, fatal disease characterized by deposition of extracellular misfolded transthyretin (TTR) in the myocardium. Eplontersen is an N-acetylgalactosamine ligand–conjugated antisense oligonucleotide targeting hepatocyte TTR messenger RNA to reduce the production of circulating TTR. METHODS: CARDIO-TTRansform is a Phase 3, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of eplontersen in transthyretin amyloidosis with cardiomyopathy. Key inclusion criteria include histological evidence of amyloid deposits or grade 2 to 3 cardiac uptake on cardiac scintigraphy in the absence of plasma cell dyscrasia, New York Heart Association class I–III, and end-diastolic interventricular septum thickness >12 millimeters. Participants were randomized 1:1 to receive eplontersen 45 mg or placebo, administered subcutaneously every 4 weeks for up to 140 weeks, followed by a 20-week post-treatment evaluation period or open-label extension. Participants received locally available standard of care, including unrestricted use of TTR stabilizers. The primary end point is a composite of cardiovascular mortality and recurrent clinical cardiovascular events through 140 weeks. Secondary end points, in order of testing hierarchy, include changes from baseline in 6-minute walk distance and Kansas City Cardiomyopathy Questionnaire overall summary score, recurrent cardiovascular events, all-cause mortality, the primary end point in the patient subgroup receiving stabilizers at baseline, and cardiovascular mortality. Echocardiography was performed in all participants, with cardiovascular magnetic resonance imaging and technetium scintigraphy in a subset. CONCLUSIONS: CARDIO-TTRansform is fully enrolled, with 1432 randomized participants who were dosed with study drug or placebo. As the largest transthyretin amyloidosis with cardiomyopathy study to date, it will evaluate whether eplontersen improves cardiovascular outcomes in patients receiving locally available standard of care, including TTR stabilizers. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04136171. URL: http://ClinicalTrialsRegister.eu ; Unique identifier: EudraCT number 2019-002835-27.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialCardiomyopathiesOligonucleotides, AntisensePrealbuminAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodOligonucleotidesTreatment Outcome

Stichwörter der Autor:innen

amyloidosiscardiomyopathieseplontersenheart failuretransthyretin

Substanzen

eplontersenOligonucleotidesOligonucleotides, AntisensePrealbuminTTR protein, human

Autor:innen und Institutionen

  • Division of Cardiovascular Medicine, Oregon Health and Sciences University, Portland (A.M.).
  • Tuscan Regional Amyloidosis Center, Department of Clinical and Experimental Medicine, University Hospital Careggi, Florence, Italy (F.C.).
  • Division of Cardiology, University of British Columbia, Vancouver, Canada (M.K.D.).
  • National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital, United Kingdom (M.F., J.D.G.).
  • Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV and Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain (P.G.-P.).
  • Department of Cardiovascular Medicine, Cleveland Clinic, OH (M.H.).

ORCID-Profile: Ahmad Masri, Francesco Cappelli, Marianna Fontana, Pablo Garcia-Pavia, Julian D Gillmore, Laura Obici, Scott D Solomon, Brett W Sperry, Nobuhiro Tahara, Márcia Waddington-Cruz, Rodney H Falk, Sanjiv J Shah, Jose Nativi-Nicolau, Sotirios Tsimikas, Mathew S Maurer

Förderung

  • NIA NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Masri, A., Cappelli, F., Davis, M. K., Fontana, M., Garcia-Pavia, P., Gillmore, J. D., Hanna, M., Obici, L., Solomon, S. D., Sperry, B. W., Tahara, N., Waddington-Cruz, M., Kristen, A. V., Falk, R. H., Shah, S. J., Nativi-Nicolau, J., Viney, N. J., Yang, Q., Chen, J., …, & Maurer, M. S. (2026). Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy. Circulation: Heart Failure, 19(6). https://doi.org/10.1161/circheartfailure.126.014205

Vancouver

Masri A, Cappelli F, Davis MK, Fontana M, Garcia-Pavia P, Gillmore JD, et al. Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy. Circulation: Heart Failure. 2026;19(6). doi:10.1161/circheartfailure.126.014205

BibTeX
@article{Masri2026,
  author = {Masri, Ahmad and Cappelli, Francesco and Davis, Margot K and Fontana, Marianna and Garcia-Pavia, Pablo and Gillmore, Julian D and Hanna, Mazen and Obici, Laura and Solomon, Scott D and Sperry, Brett W and Tahara, Nobuhiro and Waddington-Cruz, Márcia and Kristen, Arnt V and Falk, Rodney H and Shah, Sanjiv J and Nativi-Nicolau, Jose and Viney, Nicholas J and Yang, Qingqing and Chen, Jersey and Tsimikas, Sotirios and Maurer, Mathew S},
  title = {Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy},
  journal = {Circulation: Heart Failure},
  year = {2026},
  volume = {19},
  number = {6},
  doi = {10.1161/circheartfailure.126.014205}
}
Kostenlos starten →